 
      Sophiris Bio Inc. is a late-stage biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin is in Phase 2 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH). Source
No articles found.
 
                  Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing a...
Supernus Pharmaceuticals, Inc. is a pharmaceuti...
 
                  Ekso BionicsÂŽ is a pioneer in the field of robotics. For over a decade we have be...
Ekso BionicsÂŽ is a pioneer in the field of rob...
 
                  ConforMIS is a medical technology company that uses its proprietary iFitÂŽ Image-t...
ConforMIS is a medical technology company that ...
 
                  We have used biochemical, molecular & cell biology and in vivo models to screen, i...
We have used biochemical, molecular & cell biol...
 
                  Vaccinex is a clinical-stage biotechnology company engaged in the discovery and de...
Vaccinex is a clinical-stage biotechnology comp...
 
                  Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on ...
Karyopharm Therapeutics is an innovation-driven...
 
                  LivaNova is a global medical technology company built on decades of experience and...
LivaNova is a global medical technology company...
Join the National Investor Network and get the latest information with your interests in mind.